| umls-concept:C1328193 | skos:definition | NCI: A substance that is being studied in the treatment of prostate cancer. It belongs to the family of drugs called endothelin-receptor antagonists.,PDQ: An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. ZD4054 binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355727&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355727&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48430" NCI Thesaurus) | lld:umls |
